BioLamina Secures €20M EIB Loan to Scale Laminin Technology for Cell Therapy Manufacturing
Key Insights
The European Investment Bank (search) has provided €20 million in venture debt financing to Swedish biotech BioLamina (search) to expand production of laminin (search)-based cell culture matrices used in stem cell therapy development.
BioLamina (search)'s proprietary Biolaminin (search)® products consist of full-length human recombinant laminin (search) proteins that provide more biologically faithful conditions for growing therapeutic cells compared to truncated or non-human alternatives.
The funding will support scaling of laminin (search) technologies for next-generation cell therapies targeting type 1 diabetes (search), Parkinson's disease (search), heart failure (search), acute liver failure (search), and cancer (search).
The European Investment Bank (search) has announced a €20 million venture debt financing agreement with Swedish biotechnology company BioLamina (search) to expand production of specialized protein matrices essential for cell therapy manufacturing. The Stockholm-based company produces laminin (search)-based scaffolding that enables researchers and pharmaceutical companies to grow, expand, and differentiate stem cells reliably for therapeutic applications.
Core Technology and Market Position
BioLamina (search)'s flagship product line, Biolaminin (search)®, consists of full-length human recombinant laminin (search) proteins that replicate the natural cellular environment. These proteins serve as key structural components of the basement membrane and trigger cell-type-specific responses including adhesion, survival, differentiation, and organization. According to the company, most commercial alternatives use truncated or non-human versions of these proteins, while BioLamina's full-length human laminins provide more biologically faithful conditions and therefore more consistent, reproducible, and clinically compliant cell products.
The company sits at an enabling layer of the cell therapy ecosystem, rather than developing therapies directly. Its products are already widely used by academic institutions, biotechnology firms, and major pharmaceutical companies, positioning BioLamina (search) as a critical enabler in the global biotech ecosystem.
Therapeutic Applications and Partnerships
Cell therapies grown on laminin (search) matrices have broad therapeutic potential for treating conditions that are currently difficult to treat or have no cure. These applications include type 1 diabetes (search) through generation of insulin-producing beta cells, Parkinson's disease (search), heart failure (search), acute liver failure (search), and various forms of cancer (search).
BioLamina (search) has established strategic partnerships with major industry players, including collaborations with Novo Nordisk on stem cell therapies for diabetes and a partnership with Cell X Technologies (search) for iPSC-based therapeutic manufacturing workflows.
Addressing Manufacturing Bottlenecks
CEO Klaus Langhoff-Roos emphasized the critical timing of the investment, stating that "Cell therapies are rapidly moving from scientific promise to clinical reality, but scaling the production of high-quality cell products remains a fundamental challenge. This financing allows us to expand our technology and manufacturing capabilities at a critical time."
The funding addresses one of the biggest bottlenecks in regenerative medicine: the ability to produce high-quality, reproducible cell lines at scale. By providing a consistent and animal-free platform for cell cultivation, BioLamina (search)'s technology could significantly accelerate the commercialization of regenerative treatments.
Animal-Free Drug Testing Innovation
Beyond cell therapy applications, the EIB loan will support BioLamina (search)'s development of animal-free drug safety testing methods. Traditional animal-based testing methods often fail to accurately predict human responses, leading to costly late-stage failures in drug development. The company's human cell-based platforms offer a more reliable and scalable alternative, potentially improving both the safety and efficiency of pharmaceutical research.
Industry analysts estimate that improved preclinical testing methods could save billions in drug development costs while significantly shortening time-to-market for new therapies.
Strategic Investment Framework
The financing is backed by the European Union's InvestEU programme and aligns with broader EU strategies including TechEU and BioTechEU, which aim to position Europe as a global leader in high-impact innovation sectors. EIB Vice-President Karl Nehammer emphasized the importance of scaling homegrown scientific breakthroughs, stating: "Europe needs to turn scientific excellence into global companies. By supporting BioLamina (search)'s growth, we are helping ensure that cutting-edge innovation in life sciences can scale in Europe, creating jobs, strengthening competitiveness and ultimately improving public health."
Company Background and Funding History
Founded in 2008 on research from Dr. Karl Tryggvason's laboratory at the Karolinska Institutet and Duke-NUS Medical School, BioLamina (search) is headquartered in Sundbyberg in Greater Stockholm and employs approximately 100 to 117 people. The company's principal shareholders include Swedish investment company Bure Equity AB (search), Lauxera Capital Partners (search), the Tryggvason family, and Northislet.
The €20 million EIB loan represents the company's first disclosed debt financing and follows a €19 million equity financing round completed in July 2024, led by Lauxera Capital Partners (search). The venture debt structure allows BioLamina (search) to expand operations without immediate dilution of shareholder value while extending its financial runway.
Market Impact and Future Outlook
The global biotechnology market is projected to surpass $1 trillion in value over the coming decade, driven by advances in genomics, personalized medicine, and cell-based therapies. BioLamina (search)'s expansion with EIB support reflects Europe's strategic effort to compete in this rapidly growing sector and strengthen its position against the United States and Asia in biotechnology innovation.
The funding will enable BioLamina (search) to expand and scale up production of laminins to meet growing global demand, optimize manufacturing processes for greater efficiency and consistency, broaden its product portfolio to support diverse therapeutic applications, and strengthen its research and technological capabilities.